In murine glioblastoma models, treatment with STING agonists associated with biodegradable intracranial implants has demonstrated a profound shift in the tumor immune landscape, with massive intratumoral infiltration of innate immune cells, such as NK cells, and an increase in survival (89). The gene discussed is STING1; the disease is neoplasm.